1. 3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement. (September 2015) Authors: Varga, A.; Camidge, D.R.; Sequist, L.V.; Wakelee, H.; Ou, S.H.; Goldman, J.W.; Papadimitrakopoulou, V.; Gadgeel, S.; Mekhail, T.; Oxnard, G.R.; Socinski, M.; Solomon, B.; Yu, H.; Matheny, S.; Despain, D.; Soria, J.C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S598 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3088 Efficacy of rociletinib (co-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) assessed with a plasma EGFR test. (September 2015) Authors: Gadgeel, S.; Soria, J.C.; Goldman, J.W.; Wakelee, H.; Camidge, D.R.; Yu, H.; Varga, A.; Solomon, B.; Oxnard, G.R.; Ou, S.H.; Papadimitrakopoulou, V.; Liu, S.V.; Reckamp, K.; Spira, A.; Piotrowska, Z.; Despain, D.; Karlovich, C.; Yurasov, S.; Sequist, L.V. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S628 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial. (September 2015) Authors: Soria, J.C.; Goldman, J.W.; Wakelee, H.; Gadgeel, S.; Camidge, D.R.; Solomon, B.; Yu, H.; Oxnard, G.R.; Ou, S.H.; Papadimitrakopoulou, V.; Perol, M.; Reckamp, K.; Varga, A.; Dziadziuszko, R.; Chouaid, C.; Cortot, A.; Do, P.; Moro-Sibilot, D.; Poudenx, M.; Sequist, L.V. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S637 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling. (October 2020) Authors: Bendell, J.; Ulahannan, S.; Koczywas, M.; Brahmer, J.; Capasso, A.; Eckhardt, S.G.; Gordon, M.; McCoach, C.; Nagasaka, M.; Ng, K.; Pacheco, J.; Riess, J.; Spira, A.; Steuer, C.; Dua, R.; Chittivelu, S.; Masciari, S.; Wang, Z.; Wang, X.; Ou, S.H. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study. (October 2022) Authors: Ou, S.H.; Moreno Garcia, V.; Gil Bazo, I.; Prenen, H.; Moreno, I.; Johnson, M.; Castañón Álvarez, E.; Nagasaka, M.; Adeyemi, S.; Barasa, B.; Bol, K.; Doze, P.; Engbers, A.; Joe, A.K.; Stalbovskaya, V.; Laus, G.; Call, J. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S122 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗